[go: up one dir, main page]

NO300925B1 - Xantinderivater - Google Patents

Xantinderivater Download PDF

Info

Publication number
NO300925B1
NO300925B1 NO934792A NO934792A NO300925B1 NO 300925 B1 NO300925 B1 NO 300925B1 NO 934792 A NO934792 A NO 934792A NO 934792 A NO934792 A NO 934792A NO 300925 B1 NO300925 B1 NO 300925B1
Authority
NO
Norway
Prior art keywords
compound
mmol
lower alkyl
methyl
nmr
Prior art date
Application number
NO934792A
Other languages
English (en)
Norwegian (no)
Other versions
NO934792L (no
NO934792D0 (no
Inventor
Fumio Suzuki
Junichi Shimada
Nobuaki Koike
Hiroshi Kase
Joji Nakamura
Shizuo Shiozaki
Hiromi Nonaka
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of NO934792D0 publication Critical patent/NO934792D0/no
Publication of NO934792L publication Critical patent/NO934792L/no
Publication of NO300925B1 publication Critical patent/NO300925B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO934792A 1992-12-24 1993-12-23 Xantinderivater NO300925B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP34411692 1992-12-24

Publications (3)

Publication Number Publication Date
NO934792D0 NO934792D0 (no) 1993-12-23
NO934792L NO934792L (no) 1994-06-27
NO300925B1 true NO300925B1 (no) 1997-08-18

Family

ID=18366763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934792A NO300925B1 (no) 1992-12-24 1993-12-23 Xantinderivater

Country Status (6)

Country Link
US (1) US5670498A (fr)
EP (1) EP0607607B1 (fr)
AT (1) ATE143019T1 (fr)
CA (1) CA2112031A1 (fr)
DE (1) DE69304883T2 (fr)
NO (1) NO300925B1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1823895A (en) * 1994-02-23 1995-09-11 Kyowa Hakko Kogyo Co. Ltd. Xanthine derivative
US6727259B2 (en) 1997-09-05 2004-04-27 Kyowa Hakko Kogyo Co., Ltd. Remedial agent for neural degeneration
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
EP1234576B1 (fr) * 1999-10-29 2006-03-08 Kyowa Hakko Kogyo Co., Ltd. Remedes contre les troubles de l'alimentation
WO2001062979A2 (fr) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Procede permettant d'identifier des agonistes partiels du recepteur a¿2a?
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US7148229B2 (en) * 2003-02-19 2006-12-12 Hoffman-La Roche Inc. Sulfonamide substituted xanthine derivatives
TWI346114B (en) * 2003-09-29 2011-08-01 Method for stabilization of diarylvinylene compounds
ES2532479T3 (es) * 2004-01-28 2015-03-27 Kyowa Hakko Kirin Co., Ltd. Agentes para el tratamiento de la migraña
AU2005295437B2 (en) 2004-10-20 2011-05-19 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
ES2593028T3 (es) 2006-02-03 2016-12-05 Gilead Sciences, Inc. Proceso para preparar un agonista de receptor de adenosina A2A y sus polimorfos
RU2459626C2 (ru) * 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
EP2066232A1 (fr) * 2006-09-29 2009-06-10 Cv Therapeutics, Inc. Procédés d'imagerie myocardique chez des patients ayant un historique de maladie pulmonaire
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
US8871751B2 (en) * 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
CA2737077A1 (fr) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinaisons d'agent de regulation de la frequence cardiaque et d'antagoniste de recepteur a-2-alpha utilisees dans des procedes de tomographie a detecteurs multiples assistee par ordinateur
WO2020125779A1 (fr) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. Dérivés de styryl xanthine substitués en position 8 et leurs utilisations
CN111333648B (zh) * 2019-04-24 2021-05-11 东莞市东阳光新药研发有限公司 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
AU2021235803A1 (en) * 2020-03-10 2022-09-29 Marvel Biotechnology Purine compounds for treating disorders
CN113248505B (zh) * 2021-06-09 2021-09-21 南京安杰新生物医药有限公司 伊曲茶碱去甲基杂质的制备方法
WO2023097402A1 (fr) * 2021-12-03 2023-06-08 Marvel Biotechnology Composés de purine pour le traitement de troubles

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US5270316A (en) * 1989-10-20 1993-12-14 Kyowa Hakko Kogyo Co., Ltd. Condensed purine derivatives
WO1992006976A1 (fr) * 1990-10-18 1992-04-30 Kyowa Hakko Kogyo Co., Ltd. Derive de xanthine

Also Published As

Publication number Publication date
ATE143019T1 (de) 1996-10-15
CA2112031A1 (fr) 1994-06-25
NO934792L (no) 1994-06-27
US5670498A (en) 1997-09-23
NO934792D0 (no) 1993-12-23
DE69304883D1 (de) 1996-10-24
EP0607607A1 (fr) 1994-07-27
EP0607607B1 (fr) 1996-09-18
DE69304883T2 (de) 1997-05-15

Similar Documents

Publication Publication Date Title
NO300925B1 (no) Xantinderivater
EP1319003B1 (fr) Xanthines, inhibiteurs de la phosphodiesterase de type v
US7625881B2 (en) Prodrugs of A2B adenosine receptor antagonists
US7521554B2 (en) A2B adenosine receptor antagonists
WO1995023148A1 (fr) Derive de la xanthine
AU2001291022A1 (en) Xanthine phosphodiesterase v inhibitors
ES2218439T3 (es) Indoloquinazolinonas.
US7776868B2 (en) Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists
EP0559893A1 (fr) Derive de xanthine
JPH0616559A (ja) パーキンソン病治療剤
US6187780B1 (en) Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
CN111303147B (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
EP0386722B1 (fr) Dérivés de l'imidazoquinolone
EP1440075B1 (fr) Nouveaux derives amides heteroaromatiques de 3beta-amino azabicyclooctane, leur procede de preparation et leurs applications en therapeutique
JP2002512246A (ja) 非対称的に置換した新規キサンチン誘導体、その製造方法及びそのアデノシン拮抗作用を有する医薬としての使用
JP3165769B2 (ja) キサンチン誘導体
JP2988692B2 (ja) イミダゾキノロン誘導体
GB2107709A (en) Xanthines
JP2988683B2 (ja) イミダゾキノロン誘導体
CA2084669C (fr) [3h,7h]thiazolo[3,4-a]pyridines ayant une action anti-asthmatique et anti-inflammatoire sur les voies respiratoires
US20130096135A1 (en) Selected Inhibitors of Protein Tyrosine Kinase Activity
JP2843671B2 (ja) キサンチン誘導体
JPH01156978A (ja) 新規なキサンチン誘導体

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees